» Articles » PMID: 22522615

Progressive Axonal Dysfunction Precedes Development of Neuropathy in Type 2 Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2012 Apr 24
PMID 22522615
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the development of diabetic neuropathy, the current study examined changes in peripheral axonal function. Nerve excitability techniques were undertaken in 108 type 2 diabetic patients with nerve conduction studies (NCS), HbA(1c) levels, and total neuropathy score (TNS). Patients were categorized into two cohorts: patients with diabetes without neuropathy (DWN group [n = 56]) and patients with diabetes with neuropathy (DN group [n = 52]) and further into severity grade 0 (TNS 0-1 [n = 35]), grade 1 (TNS 2-8 [n = 42]), and grade 2/3 (TNS 9-24 [n = 31]). Results revealed that the DWN group had a significantly increased threshold, prolonged latency, and changes in excitability parameters compared with age-matched control subjects. Patients with neuropathy demonstrated significant alteration in recovery cycle parameters and depolarizing threshold electrotonus. Within the DWN cohort, there were significant correlations between HbA(1c) level and latency and subexcitability, whereas the estimated glomerular filtration rate correlated with superexcitability in patients with neuropathy. Furthermore, excitability parameters became progressively more abnormal with increasing clinical severity. These results suggest a spectrum of excitability abnormalities in patients with diabetes and that early axonal dysfunction may be detected prior to the development of neuropathy. As progressive changes in excitability parameters correlated to neuropathy severity, excitability testing may provide a biomarker of the early development and severity of diabetic neuropathy, providing insights into the pathophysiological mechanisms producing axonal dysfunction.

Citing Articles

Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods.

Roikjer J, Borbjerg M, Andresen T, Giordano R, Hviid C, Morch C J Diabetes Sci Technol. 2024; :19322968241279553.

PMID: 39282925 PMC: 11571639. DOI: 10.1177/19322968241279553.


Diagnostic Accuracy of Perception Threshold Tracking in the Detection of Small Fiber Damage in Type 1 Diabetes.

Roikjer J, Croosu S, Sejergaard B, Hansen T, Frokjaer J, Sondergaard C J Diabetes Sci Technol. 2023; 18(5):1157-1164.

PMID: 36825610 PMC: 11418516. DOI: 10.1177/19322968231157431.


Recent updates in the treatment of diabetic polyneuropathy.

Fan Q, Smith A Fac Rev. 2022; 11:30.

PMID: 36311537 PMC: 9586156. DOI: 10.12703/r/11-30.


Diagnostic accuracy of nerve ultrasonography for the detection of peripheral neuropathy in type 2 diabetes.

Dhanapalaratnam R, Issar T, Poynten A, Milner K, Kwai N, Krishnan A Eur J Neurol. 2022; 29(12):3571-3579.

PMID: 36039540 PMC: 9826521. DOI: 10.1111/ene.15534.


Axonal Excitability Does Not Differ between Painful and Painless Diabetic or Chemotherapy-Induced Distal Symmetrical Polyneuropathy in a Multicenter Observational Study.

Themistocleous A, Kristensen A, Sola R, Gylfadottir S, Bennedsgaard K, Itani M Ann Neurol. 2022; 91(4):506-520.

PMID: 35150149 PMC: 9313833. DOI: 10.1002/ana.26319.


References
1.
Dyck P, Kratz K, Karnes J, Litchy W, Klein R, Pach J . The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993; 43(4):817-24. DOI: 10.1212/wnl.43.4.817. View

2.
van Schie C . Neuropathy: mobility and quality of life. Diabetes Metab Res Rev. 2008; 24 Suppl 1:S45-51. DOI: 10.1002/dmrr.856. View

3.
Erdogan C, Yucel M, Degirmenci E, Oz O, Akgun H, Odabasi Z . Nerve excitability properties in early preclinical diabetic neuropathy. Diabetes Res Clin Pract. 2011; 94(1):100-4. DOI: 10.1016/j.diabres.2011.06.011. View

4.
Sundkvist G, Dahlin L, Nilsson H, Eriksson K, Lindgarde F, Rosen I . Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med. 2000; 17(4):259-68. DOI: 10.1046/j.1464-5491.2000.00261.x. View

5.
Zhang W, Yorek M, Pierson C, Murakawa Y, Breidenbach A, Sima A . Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res. 2002; 2(3):187-93. PMC: 2478548. DOI: 10.1155/edr.2001.187. View